How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

14,057 results for

aspirin (adverse effects OR side effects)

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Acetylsalicylic acid (aspirin) for schizophrenia. (Abstract)

Acetylsalicylic acid (aspirin) for schizophrenia. Schizophrenia is a serious chronic mental illness affecting an estimated 21 million people worldwide and there is increasing evidence linking inflammation in the brain to the pathophysiology of schizophrenia. Antipsychotic drugs are the conventional treatment for people with schizophrenia but are not always fully effective. Acetylsalicylic acid (aspirin) is a non-steroidal anti-inflammatory drug (NSAID) with properties that inhibit (...) the proinflammatory status of the brain. Using aspirin as an adjunct (add-on) treatment to antipsychotics or as a stand-alone treatment could be a novel, relatively inexpensive option for people with schizophrenia.To review the effects of acetylsalicylic acid (aspirin) as adjunct (add-on) or as stand-alone treatment for people with schizophrenia.We searched the Cochrane Schizophrenia Group's Trials Register (last search 8 March 2018) which is based on regular searches of MEDLINE, Embase, PubMed, CINAHL, BIOSIS

2019 Cochrane

2. Clopidogrel / Acetylsalicylic acid Mylan

are being taken to ensure the safe and effective use of Clopidogrel/Acetylsalicylic acid Mylan? Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Clopidogrel/Acetylsalicylic acid Mylan have been included in the summary of product characteristics and the package leaflet. As for all medicines, data on the use of Clopidogrel/Acetylsalicylic acid Mylan are continuously monitored. Side effects reported with Clopidogrel/Acetylsalicylic (...) /Acetylsalicylic acid Mylan contains two active substances, clopidogrel and acetylsalicylic acid (also known as aspirin) and is a ‘generic medicine’. This means that Clopidogrel/Acetylsalicylic acid Mylan contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called DuoPlavin. For more information on generic medicines, see the question-and-answer document here. How is Clopidogrel/Acetylsalicylic acid Mylan used? The medicine is available as tablets

2020 European Medicines Agency - EPARs

3. Rivaroxaban (Xarelto) - Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients

submission rivaroxaban (Xarelto ® ) is accepted for restricted use within NHSScotland. Indication under review: Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with: - coronary artery disease, or - symptomatic peripheral artery disease at high risk of ischaemic events. SMC restriction: use in patients with stable coronary artery disease that does not require dual antiplatelet therapy. Addition of rivaroxaban to low-dose aspirin (acetylsalicylic (...) acid) reduced the incidence of a composite outcome that included stroke, cardiovascular death and myocardial infarction, mainly due to reductions in stroke and cardiovascular death. It also increased the incidence of major bleeding. Chairman Scottish Medicines Consortium www.scottishmedicines.org.uk 2 Indication Co-administered with acetylsalicylic acid (aspirin) for the prevention of atherothrombotic events in adult patients with: - coronary artery disease, or - symptomatic peripheral artery

2019 Scottish Medicines Consortium

4. Acetyl Salicylic Acid (ASA)

Acetyl Salicylic Acid (ASA) © 2015 Thrombosis Canada Page 1 of 4 ACETYL SALICYLIC ACID (ASA) OBJECTIVE: To provide information on the use of acetyl salicylic acid in the prevention of vascular thromboembolic events. BACKGROUND: Acetyl salicylic acid (ASA) is well-established in the management of acute myocardial infarction and in the secondary prevention of cardiovascular disease among both men and women, based on large randomized trials. More recently, its role in the prevention of recurrent (...) OF ASA: ? Bruising is very common with use of ASA ? Dyspepsia ? The most common serious adverse effect of ASA is bleeding into the gastrointestinal tract (which is dose-related) ? Allergic reactions, asthma (may be severe) PERI-PROCEDURAL MANAGEMENT FOR PATIENTS TAKING ASA: Patients receiving ASA and: a) undergoing an invasive diagnostic test, i. associated with a low risk of bleeding, should continue ASA without interruption. ii. associated with a high risk of bleeding, should discontinue ASA 7 days

2015 Thrombosis Interest Group of Canada

5. Salicylic acid peeling combined with vitamin C mesotherapy versus salicylic acid peeling alone in the treatment of mixed type melasma: A comparative study. (Abstract)

Salicylic acid peeling combined with vitamin C mesotherapy versus salicylic acid peeling alone in the treatment of mixed type melasma: A comparative study. Melasma is a distressing condition for both dermatologists and patients. We evaluated the effectiveness of salicylic acid (SA) peel and vitamin C mesotherapy in the treatment of melasma.Fifty female patients were divided into two groups. All patients were treated with 30% SA peel every two weeks for two months. In addition, after SA peeling (...) noted.The MelasQoL and MASI scores of patients in both groups significantly decreased after the treatment. Apart from a burning sensation, no adverse event was observed and all patients tolerated the treatment well.SA peel combined with vitamin C mesotherapy is a safe and effective alternative for the treatment of melasma with no significant side effects and minimal downtime.

2018 Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology Controlled trial quality: uncertain

6. Clopidogrel/Acetylsalicylic acid Teva

2.5. Clinical safety 30 2.6. Pharmacovigilance 33 2.7. Risk Management Plan 34 2.8. Product information 39 3. Benefit-Risk Balance 39 Benefit-risk balance 41 4. Recommendations 42 Medicinal product no longer authorised Assessment report EMA/502333/2014 Page 3/43 List of abbreviations AA Arachidonic acid ACE Angiotensin converting enzyme ACS Acute coronary syndrome ADP Adenosine diphosphate AE Adverse event Al(u) Aluminium ANOVA Analysis of variance ASA Acetylsalicylic acid AUC Area under the curve (...) platelet membrane microdomains. The activity of clopidogrel on platelet aggregation was appropriately evaluated in vitro and ex vivo. Acetylsalicylic acid (ASA) ASA inhibits platelet aggregation by irreversible inhibition of prostaglandin cyclo-oxygenase and thus inhibits the generation of thromboxane A2, an inducer of platelet aggregation and vasoconstriction. This effect lasts for the life of the platelet. The pharmacological profile of ASA as a cyclooxygenase (COX) inhibitor (both COX-1 and COX-2

2014 European Medicines Agency - EPARs

7. Salicylic Acid Alleviates the Adverse Effects of Salt Stress on Dianthus superbus (Caryophyllaceae) by Activating Photosynthesis, Protecting Morphological Structure, and Enhancing the Antioxidant System Full Text available with Trip Pro

Salicylic Acid Alleviates the Adverse Effects of Salt Stress on Dianthus superbus (Caryophyllaceae) by Activating Photosynthesis, Protecting Morphological Structure, and Enhancing the Antioxidant System Salt stress critically affects the physiological processes and morphological structure of plants, resulting in reduced plant growth. Salicylic acid (SA) is an important signal molecule that mitigates the adverse effects of salt stress on plants. Large pink Dianthus superbus L. (Caryophyllaceae (...) ), there was no significant difference in the plant growth and physiological responses between SA-treated and non-SA-treated plants. Therefore, our research suggests that exogenous SA can effectively counteract the adverse effect of moderate salt stress on D. superbus growth and development.

2017 Frontiers in plant science

8. Cost-Utility and Budget Impact Analysis for Stopping the Inappropriate Use of Proton Pump Inhibitors After Cessation of NSAID or Low-Dose Acetylsalicylic Acid Treatment. Full Text available with Trip Pro

Cost-Utility and Budget Impact Analysis for Stopping the Inappropriate Use of Proton Pump Inhibitors After Cessation of NSAID or Low-Dose Acetylsalicylic Acid Treatment. In accordance with current guidelines, proton pump inhibitors (PPIs) are now generally prescribed as a protective co-medication in patients taking non-steroidal anti-inflammatory drugs (NSAIDs) or low-dose acetylsalicylic acid (LDASA). However, less attention is paid to the corresponding discontinuation of a PPI after cessation (...) of NSAID or LDASA treatment.The aim of this study was to assess the extent of inappropriate PPI use, as the proportion of patients who started a PPI as a protective co-medication but continued using these drugs after cessation of NSAID and LDASA treatment. We also sought to estimate the potential cost savings and effect gains of discontinuing inappropriate PPI use and the resulting decrease in adverse effects and their detrimental consequences.Pharmacy dispensing data were used to map inappropriate PPI

2019 Drugs & Aging

9. Bifidobacteriumbreve Bif195 Protects Against Small-Intestinal Damage Caused by Acetylsalicylic Acid in Healthy Volunteers. Full Text available with Trip Pro

Bifidobacteriumbreve Bif195 Protects Against Small-Intestinal Damage Caused by Acetylsalicylic Acid in Healthy Volunteers. Enteropathy and small-intestinal ulcers are common adverse effects of nonsteroidal anti-inflammatory drugs such as acetylsalicylic acid (ASA). Safe, cytoprotective strategies are needed to reduce this risk. Specific bifidobacteria might have cytoprotective activities, but little is known about these effects in humans. We used serial video capsule endoscopy (VCE) to assess (...) ) than in the placebo group (75.2 ± 85.3 arbitrary units) (P = .0258). Twelve adverse events were reported from the Bif195 group and 20 from the placebo group. None of the events was determined to be related to Bif195 intake.In a randomized, double-blind trial of healthy volunteers, we found oral Bif195 to safely reduce the risk of small-intestinal enteropathy caused by ASA. ClinicalTrials.gov no: NCT03228589.Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

2019 Gastroenterology Controlled trial quality: predicted high

10. Meta-Analysis of Acetylsalicylic Acid Desensitization in Patients With Acute Coronary Syndrome. (Abstract)

Meta-Analysis of Acetylsalicylic Acid Desensitization in Patients With Acute Coronary Syndrome. Acetylsalicylic acid (ASA) hypersensitivity represents a clinical challenge in acute coronary syndrome (ACS) patients urgently requiring ASA for antiplatelet therapy. ASA desensitization has been reported with successful outcomes in cardiac patients. The aim of this review is to determine the safety and efficacy of ASA desensitization therapy in ACS patients. A PubMed database search was conducted (...) for articles containing combinations of keywords, "aspirin desensitization" or "aspirin hypersensitivity" and "acute coronary syndrome" between January 1, 1990 and August 1, 2018. The primary end point was desensitization protocol success. Secondary end points included hypersensitivity adverse events and ASA discontinuation due to hypersensitivity adverse events at follow-up. Fifteen reports consisting of 480 ACS patients with previous hypersensitivity to ASA were included. The pooled desensitization

2019 American Journal of Cardiology

11. Is there Evidence to Support the use of Enteric Coated (EC) Aspirin to Reduce Gastrointestinal Side Effects in Patients with Cardiovascular Disease?

Is there Evidence to Support the use of Enteric Coated (EC) Aspirin to Reduce Gastrointestinal Side Effects in Patients with Cardiovascular Disease? Is there Evidence to Support the use of Enteric Coated (EC) Aspirin to Reduce Gastrointestinal Side Effects in Patients with Cardiovascular Disease? – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice Menu · · 10th January 2020 · London and South East Regional Medicines Information The enteric coated (EC (...) ) formulation of aspirin was developed and marketed in an effort to reduce GI adverse effects associated with aspirin therapy. There are reports however, that EC does not significantly reduce the risk of GI bleeding when compared to standard formulations of aspirin. There is also speculation that enteric coating may reduce the anti-platelet effect of aspirin due to a reduction in bioavailability, thereby reducing its clinical efficacy in prevention of cardiovascular events. This Q&A reviews the evidence

2020 Specialist Pharmacy Services

12. Chlorpheniramine Potentiates the Analgesic Effect in Migraine of Usual Caffeine, Acetaminophen, and Acetylsalicylic Acid Combination Full Text available with Trip Pro

acetylsalicylic acid (ASA), 150 mg acetaminophen (paracetamol, PAR), 30 mg caffeine (CAF) and 4 mg chlorpheniramine (CLF) vs. a combination containing 250 mg ASA, 250 mg PAR, and 65 mg CAF recognized as "safe and effective" by FDA in treating migraine. Patients evaluated their pain intensity on the Visual Analog Scale-VAS(PI) before and 30, 60, 120, 180, and 240 min after drug intake. Interpretation of the pain curves as "survival pain curves" was considered as a method for direct comparison of the pain (...) Chlorpheniramine Potentiates the Analgesic Effect in Migraine of Usual Caffeine, Acetaminophen, and Acetylsalicylic Acid Combination Previous studies indicated that addition of the antihistaminic chlorpheniramine to the usual combination of acetylsalicylic acid, acetaminophen, and caffeine further increases their synergism both in terms of anti-inflammatory and analgesic effect. The present non-interventional study tested the superiority of two Algopirin® tablets, containing a total of 250 mg

2017 Frontiers in pharmacology

13. Cost Effectiveness of Gastroprotection with Proton Pump Inhibitors in Older Low-Dose Acetylsalicylic Acid Users in the Netherlands. Full Text available with Trip Pro

Cost Effectiveness of Gastroprotection with Proton Pump Inhibitors in Older Low-Dose Acetylsalicylic Acid Users in the Netherlands. The present study aimed to assess the cost effectiveness of concomitant proton pump inhibitor (PPI) treatment in low-dose acetylsalicylic acid (LDASA) users at risk of upper gastrointestinal (UGI) adverse effects as compared with no PPI co-medication with attention to the age-dependent influence of PPI-induced adverse effects.We used a Markov model to compare (...) the strategy of PPI co-medication with no PPI co-medication in older LDASA users at risk of UGI adverse effects. As PPIs reduce the risk of UGI bleeding and dyspepsia, these risk factors were modelled together with PPI adverse effects for LDASA users 60-69, 70-79 (base case) and 80 years and older. Incremental cost-utility ratios (ICURs) were calculated as cost per quality-adjusted life-year (QALY) gained per age category. Furthermore, a budget impact analysis assessed the expected changes in expenditure

2017 Drugs & Aging

14. Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid

with Xarelto in combination with acetylsalicylic acid (ASA). Both drugs reduce the risk of blood clots via different pathways. The study will enroll adult patients suffering from coronary artery disease (narrowing or blockage of vessels that supply the heart with blood) or peripheral artery disease (narrowing or blockage of vessels that supply the legs or head with blood). The study will focus on information on when and why physicians are starting to treat patients with Xarelto in addition to ASA (...) , treatment duration, reasons to discontinue treatment and previous therapies. The study will also look into treatment outcomes for patients being treated with a combination of Xarelto and ASA by their physicians. Condition or disease Intervention/treatment Atherosclerosis Drug: Rivaroxaban (BAY59-7939, Xarelto) Drug: Acetylsalicylic acid Detailed Description: The study aims to collect real-world data on treatment patterns and decision points for treatment in patients with coronary artery disease (CAD

2018 Clinical Trials

15. Administration of melatonin protects against acetylsalicylic acid-induced impairment of male reproductive function in mice Full Text available with Trip Pro

Administration of melatonin protects against acetylsalicylic acid-induced impairment of male reproductive function in mice Melatonin, an important hormone secreted by the epiphysis, is a powerful anti-oxidant with a high potential to neutralize medical toxins. The goal of this study was to demonstrate the beneficial effect of melatonin on epididymal sperm and reproductive parameters in mice treated with acetylsalicylic acid (ASA).Male adult mice were divided into four treatment groups: control (...) (50 mg/kg) has adverse effects on male reproductive function in mice. Co-administration of melatonin protects against ASA-induced impairment of male reproductive function by preventing the reduction in serum TAC and testosterone levels seen with ASA treatment alone.

2018 Iranian journal of basic medical sciences

16. Comparative study of buffered 50% glycolic acid (pH 3.0) + 0.5% salicylic acid solution vs Jessner's solution in patients with acne vulgaris. (Abstract)

Comparative study of buffered 50% glycolic acid (pH 3.0) + 0.5% salicylic acid solution vs Jessner's solution in patients with acne vulgaris. Superficial chemical peels are frequently used in acne vulgaris treatment. Although glycolic acid (GA) has been widely used in clinical practice, its pH ranges from 0.08-2.75 and thus should be neutralized after application to avoid burns.To evaluate treatment efficacy and safety of chemical peeling using buffered 50% GA (pH 3.0) + 0.5% salicylic acid (SA (...) . Lesion count, acne severity, subjective efficacy assessment, and side effects were evaluated.The total lesion count was significantly reduced for the GA and Jessner's solution sides (P < .001). However, there was no significant difference in the total lesion count, acne severity, or subjective efficacy assessment between the 2 sides (P > .05). The GA side had fewer side effects than the Jessner's solution side.The results of this study suggest that chemical peeling using the 50% GA (pH 3.0) + 0.5% SA

2019 Journal of cosmetic dermatology Controlled trial quality: uncertain

17. Clinical and dermoscopic evaluation of combined (salicylic acid 20% and azelaic acid 20%) versus trichloroacetic acid 25% chemical peel in acne: a RCT. (Abstract)

Clinical and dermoscopic evaluation of combined (salicylic acid 20% and azelaic acid 20%) versus trichloroacetic acid 25% chemical peel in acne: a RCT. Combined azelaic acid (AA) and salicylic acid (SA) have not been previously used for acne.To compare the efficacy of this combination versus trichloroacetic acid (TCA) 25% peel in acne.Thirty-four patients were included in this trial. Patients received four sessions 2 weeks apart. The combined solution was applied to one side of the face, while (...) side. There was no significant different clinical improvement in both treated sides as regards SPT. Erythema improved in both sides. Patients were more satisfied by the SA/AA-treated side.Chemical peeling is effective in controlling mild-moderate acne in SPT III-IV. Combined SA 20% and AA 20% are recommended at early stage of treatment if patients have more inflammatory lesions, while TCA is recommended if patients have more non-inflammatory lesions.

2018 Journal of Dermatological Treatment Controlled trial quality: uncertain

18. [Perioperative acetylsalicylic acid and clonidine in noncardiac surgery patients (POISE-2 trial)]. (Abstract)

MN3L5RMN02 Clonidine R16CO5Y76E Aspirin IM Adrenergic alpha-2 Receptor Agonists therapeutic use Aged Aged, 80 and over Aspirin adverse effects therapeutic use Cardiovascular Diseases complications drug therapy Clonidine therapeutic use Double-Blind Method Hospital Mortality Humans Middle Aged Myocardial Infarction etiology mortality prevention & control Perioperative Care methods Platelet Aggregation Inhibitors adverse effects therapeutic use Postoperative Complications etiology mortality prevention (...) [Perioperative acetylsalicylic acid and clonidine in noncardiac surgery patients (POISE-2 trial)]. 25700958 2017 01 25 2017 01 25 2340-3284 62 5 2015 May Revista espanola de anestesiologia y reanimacion Rev Esp Anestesiol Reanim [Perioperative acetylsalicylic acid and clonidine in noncardiac surgery patients (POISE-2 trial)]. 270-4 10.1016/j.redar.2014.12.009 S0034-9356(15)00006-7 Cegarra-Sanmartin V V Departamento de Anestesiología y Reanimación, Hospital de la Santa Creu i Sant Pau, Barcelona

2017 Revista Espanola De Anestesiologia Y Reanimacion Controlled trial quality: uncertain

19. Low-dose Acetylsalicylic Acid Before Non-cardiac Surgery

for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Universitätsklinikum Hamburg-Eppendorf: Bleeding Adverse Cardiac Events Adherence, Medication Aspirin Acetylsalicylic acid Additional relevant MeSH terms: Layout table for MeSH terms Aspirin Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory (...) Study Details Study Description Go to Brief Summary: This study aims to assess independent factors associated with the clinical decision to discontinue ASA preoperatively in patients undergoing elective non-cardiac surgery. Condition or disease Intervention/treatment Surgery Platelet Dysfunction Other: preoperative questionnaires Detailed Description: Acetylsalicylic acid (ASA) is widely used for primary and secondary prevention of cardiovascular diseases. A prothrombotic rebound phenomenon after

2017 Clinical Trials

20. Acetylsalicylic Acid Plus Intensive Blood Pressure Treatment in Patients With Unruptured Intracranial Aneurysms

acid (ASA) 100 mg/day, intensive blood pressure treatment (targeted systolic blood pressure below 120 mmHg), and a blood pressure measuring device reduces the risk of aneurysm rupture or growth compared with standard care (i.e. no ASA, blood pressure management according to standard blood pressure management, no blood pressure measuring device) Condition or disease Intervention/treatment Phase Unruptured Intracranial Aneurysms Drug: Acetylsalicylic acid Other: intensive blood pressure control Phase (...) Intracranial Aneurysms Actual Study Start Date : September 21, 2017 Estimated Primary Completion Date : October 2022 Estimated Study Completion Date : October 2022 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Acetylsalicylic acid, BP-target 120 100 mg ASA plus intensified blood pressure management. Recommended systolic blood pressure 120 mm/Hg Drug: Acetylsalicylic acid 100 mg daily as one

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>